| Literature DB >> 29445220 |
Seyed Hossein Ardehali1, Salman Dehghan2, Ahmad Reza Baghestani3, Aynaz Velayati2, Zahra Vahdat Shariatpanahi4.
Abstract
To evaluate the association of admission serum levels of 25(OH)D, parathormone and the related electrolytes with severity of illness and clinical outcomes in neurosurgical critically ill patients, serum levels of 25(OH)D, parathormone, calcium, magnesium, and phosphate, along with APACHE II score were measured for 210 patients upon admission. Mean serum 25(OH)D was 21.1 ± 7.4 ng/mL. 25(OH)D deficiency (less than 20 ng/dL) and elevated serum parathormone level were found in 47.6% and 38% of patients respectively. Hypocalcaemia, hypophosphatemia, hypomagnesaemia and hypermagnesaemia were found in 29.5%, %63.8, 41.9% and 27.6% of patients respectively. The APACHE II score was significantly correlated with serum levels of 25(OH)D, parathormone, calcium, and phosphate. Multivariate regression analysis adjusted by other risk factors showed that among all clinical outcomes, admission hypovitaminosis D was associated with longer duration of ICU stay and a high admission of parathormone was associated with in ICU mortality. We concluded that disorders of admission serum levels of 25(OH)D, parathormone, calcium, magnesium, and phosphate are related to the presence of multiple causal factors such as severity of disease and are not independently associated with clinical outcomes. Most often they are normalize spontaneously with resolution of the disease process.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29445220 PMCID: PMC5813225 DOI: 10.1038/s41598-018-21177-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of patients based on 25-hydroxyvitamin D categorized groups.
| Deficiency Severe (n = 16) | Deficiency Mild (n = 84) | Insufficiency (n = 76) | Normal (n = 34) | P value | |
|---|---|---|---|---|---|
| Age (year) | 47 ± 16ab | 51 ± 12a | 42 ± 14b | 42 ± 15ab | 0.025* |
| Sex (n. %) | 0.63*** | ||||
| Male | 10 (62.5%) | 48 (57.1%) | 48 (63.2%) | 18 (52.9%) | |
| Female | 6 (7.5%) | 36 (42.9%) | 28 (36.8%) | 16 (47.1%) | |
| APACHE II, | 12.75 ± 3.7a | 11.33 ± 4.54ab | 8.42 ± 3.86bc | 8.41 ± 3.29c | 0.002* |
| Albumin (g/dL) | 2.9 ± 0.55a | 3.1 ± 0.5ab | 3.4 ± 0.35b | 3.3 ± 0.87ab | 0.02* |
| 25(OH)D (ng/dL) | 8.6 ± 0.6a | 16.08 ± 2.7b | 24.04 ± 2.5c | 33.18 ± 2.3d | 0.001* |
| Calcium (mg/dL) | 8.5 ± 0.45 | 8.7 ± 0.75 | 8.9 ± 0.7 | 8.8 ± 0.81 | 0.40* |
| Magnesium (mg/dL) | 1.75 ± 0.19 | 1.87 ± 0.32 | 1.97 ± 0.41 | 1.78 ± 0.31 | 0.22* |
| Phosphate (mg/dL) | 3.4 ± 1.1 | 3.06 ± 0.73 | 3.4 ± 0.78 | 3.3 ± 0.87 | 0.23* |
| PTH (pg/mL) | 122.4 ± 32.7a | 77.3 ± 48.7b | 56.7 ± 33.1b | 48.1 ± 31.7b | 0.001* |
| Blood glucose (g/dL) | 138.07 (87.2) | 129.6 (38.6) | 118.6 (39.9) | 118 (37.3) | 0.088* |
| Energy intake (%) | 56.1 ± 27.7 | 68.8 ± 21.9 | 61.9 ± 25.3 | 56.1 ± 21.7 | 0.19* |
| LOS1 | 17.5 (25.5)a | 13 (15)a | 4 (2)b | 3 (5.1)b | 0.001** |
| SOFA2 | 8 (3)a | 5(4)ac | 4 (4.25)c | 5 (2.5)c | 0.006** |
| MV3 (n, %) | 16 (7.6%)a | 60 (28.6%)b | 24 (12.5%)a | 8 (3.9%)a | 0.04*** |
| MV Duration | 19.6 ± 10.3a | 12.7 ± 9.7b | 4.1 ± 1.58c | 1.93 ± 0.94c | 0.001** |
| Mortality (n, %) | 12 (20.7%)a | 34 (58.6%)ab | 10 (17.2%)bc | 2 (3.4%)c | 0.001*** |
*One-way ANOVA (mean ± SD), **Man-Whitney (median, IQ), ***Chi square.
1Length of stay, 2Sequentional organ failure assessment, 3Mechanical ventilation. Values with different superscript letters are significantly different.
Logistic regression for clinical outcomes in 210 patients according to serum 25(OH)D and parathormone level.
| OR | 95% CI | P value | Adjusted OR | 95% CI | P value | |
|---|---|---|---|---|---|---|
|
| ||||||
| 25(OH)D | 0.85 | 0.78–0.92 | 0.001 | |||
| PTH | 1.03 | 1.01–1.04 | 0.001 | 1.02 | 1.002–1.040 | 0.03 |
| Calcium | 0.48 | 0.25–0.92 | 0.029 | |||
| Phosphate | 0.87 | 0.51–1.4 | 0.600 | |||
| Hypomagnesaemia | 1.15 | 0.38–3.45 | 0.852 | |||
| hypermagnesaemia | 0.85 | 0.30–2.38 | 0.760 | |||
|
| ||||||
| 25(OH)D | 0.80 | 0.74–0.88 | 0.001 | 0.89 | 0.79–0.99 | 0.04 |
| PTH | 1.01 | 1.00–1.02 | 0.001 | |||
| Calcium | 0.58 | 0.33–1.20 | 0.062 | |||
| Phosphate | 0.67 | 0.40–1.11 | 0.128 | |||
| Hypomagnesaemia | 2.04 | 0.73–5.73 | 0.174 | |||
| hypermagnesaemia | 1.32 | 0.51–3.40 | 0.563 | |||
|
| ||||||
| 25(OH)D | 0.92 | 0.87–0.98 | 0.001 | |||
| PTH | 1.01 | 1.007–1.02 | 0.001 | |||
| Calcium | 0.65 | 0.36–1.10 | 0.156 | |||
| Phosphate | 0.82 | 0.49–1.30 | 0.596 | |||
| Hypomagnesaemia | 0.75 | 0.25–2.17 | 0.455 | |||
| hypermagnesaemia | 0.37 | 0.13–1.05 | 0.060 | |||
|
| ||||||
| 25(OH)D | 0.88 | 0.79–0.97 | 0.013 | |||
| PTH | 1.01 | 0.90–1.02 | 0.114 | |||
| Calcium | 0.58 | 0.25–1.30 | 0.206 | |||
| Phosphate | 0.73 | 0.38–1.40 | 0.350 | |||
| Hypomagnesaemia | 1.35 | 0. 43–4.19 | 0.600 | |||
| Hypomagnesaemia | 0.29 | 0.41–1.62 | 0.631 | |||
1Length of stay; 2Sequential Organ Failure Assessment Score; 3Duration of mechanical ventilation.
Characteristics of patients based on serum PTH.
| Hyperparathyroidism group (n = 84) | Non hyperparathyroidism group (n = 126) | P value | |
|---|---|---|---|
| APACHE II, | 11.88 ± 4.26 | 8.81 ± 4.15 | 0.001* |
| 25(OH)D (ng/dL) | 16.55 ± 5.21 | 20.75 ± 5.21 | 0.001* |
| Calcium (mg/dL) | 8.64 ± 0.63 | 9.03 ± 0.73 | 0.01* |
| Magnesium (mg/dL) | 1.90 ± 0.39 | 1.91 ± 0.34 | 0.94* |
| Phosphate (mg/dL) | 3.13 ± 0.78 | 3.34 ± 0.82 | 0.22* |
| PTH (pg/mL) | 113.9 ± 32.59 | 38.06 ± 14.10 | 0.001* |
| LOS1 | 13 (6–28) | 5 (4–8) | 0.001** |
| SOFA2 | 7 (5–9) | 4 (3–6) | 0.001** |
| MV3 (n, %) | 68 (68%) | 32 (32%) | 0.04*** |
| Mortality (n, %) | 47 (81%) | 11 (19%) | 0.001*** |
*T test (mean ± SD), **Man-Whitney (median, IQ), ***Chi square.
1Length of stay, 2Sequentional organ failure assessment, 3Mechanical ventilation.